Gil Morgan, MD

www.gotoper.com 24th Annual School of Breast Oncology | PER This highly interactive three-day program will provide a comprehensive review of the data on the most important aspects of breast cancer biology, diagnostics...

OncoAlert Verified account @OncoAlert · 4d

School of BREAST ONCOLOGY .TOMORROW November 5th (FREE REGISTRATION)
Click Here 👉 gotoper.com/courses/school…

Atlanta or Online (HYBRID MEETING) November 5-7
FREE HCP Registration with Code: ONCOALERT

Explore the latest advances in breast cancer care with leading experts. Gain practical insights from pivotal trials, emerging evidence, and expert discussions to inform personalized treatment and clinical practice. #BreastCancer

@BCJoyceO, @DrRFreedman, @DrWGradishar, @laura_huppert, @claudine_isaacs, @KalinskyKevin, @jane_meisel, @BeverlyMoy, @oreganruth, @AnnPartridgeMD, @PierceLoriJ, @PedramRazaviMD, @hoperugo, @DrHaniSbitany, @puneetsinghmd, @jsparano @gotoPER

View quoted post on X

www.gotoper.com 24th Annual School of Breast Oncology | PER This highly interactive three-day program will provide a comprehensive review of the data on the most important aspects of breast cancer biology, diagnostics...

OncoAlert Verified account @OncoAlert · 4d

School of BREAST ONCOLOGY .TOMORROW November 5th (FREE REGISTRATION)
Click Here 👉 gotoper.com/courses/school…

Atlanta or Online (HYBRID MEETING) November 5-7
FREE HCP Registration with Code: ONCOALERT

Explore the latest advances in breast cancer care with leading experts. Gain practical insights from pivotal trials, emerging evidence, and expert discussions to inform personalized treatment and clinical practice. #BreastCancer

@BCJoyceO, @DrRFreedman, @DrWGradishar, @laura_huppert, @claudine_isaacs, @KalinskyKevin, @jane_meisel, @BeverlyMoy, @oreganruth, @AnnPartridgeMD, @PierceLoriJ, @PedramRazaviMD, @hoperugo, @DrHaniSbitany, @puneetsinghmd, @jsparano @gotoPER

View quoted post on X

OncoAlert Verified account @OncoAlert · Oct 30

DeLLphi-305🚨 A 0.42 hazard ratio for death in extensive-stage small-cell lung cancer. In a disease where we’ve celebrated gains of two to three months, this is a different level. 🫁

Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer
nejm.org/doi/full/10.10…

@MP_3855, @ADesaiMD

📊 In the open-label phase 3 DeLLphi-305 trial, 563 patients with extensive-stage SCLC without progression after first-line chemoimmunotherapy were randomized to tarlatamab plus durvalumab or durvalumab alone as maintenance. The median overall survival was 21.1 versus 12.7 months (HR 0.42), and the median PFS 7.4 versus 1.9 months (HR 0.34). Grade ≥3 adverse events occurred in 46.8% versus 40.6%; cytokine release syndrome, mostly grade 1–2, affected nearly half of tarlatamab-treated patients. #LungCancer

Pinging our faculty
@christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD

@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @JulienMazieres @TerriConneran @HenningWillers

View quoted post on X

www.oncoalert360.com ESMO 2026 highlights | OncoAlert Highlights from ESMO 2026, Madrid: daily round-ups and paper updates by the OncoAlert faculty. Free and independent.

OncoAlert Verified account @OncoAlert · Oct 29

Visit Our New Website 🚨 Science Directly From People Who Presented It
👉 oncoalert360.com/events/esmo-20…

No noise. No ads. Just oncology, for colleagues, by colleagues.

OncoAlert is with you every day, not just at congresses. Our website brings you the science you need to stay up to date, with no fluff, no distractions and no advertising.

We are a non-profit Organization with one mandate: keeping colleagues worldwide up to date. For almost a decade, OncoAlert has been made 100% by physicians, by oncologists for oncologists. Some of the biggest names in oncology are part of this network, and they use it to bring new findings directly to you.

@cdanicas · @hoperugo · @DrChoueiri · @TiansterZhang · @matteolambe · @NiuSanford · @stolaney1 · @christine_lovly · @amerseburger · @GlopesMd · @tompowles1 · @montypal · @Icro_Meattini · @PGrivasMDPhD · @brian_rini · @CathyEngMD · @apolo_andrea · @AndreaNecchi · @DrSGraff · @BenWestphalen · @graokane · @to_be_elizabeth · @ElisaAgostinett · @nataliagandur · @UOzkerim · @DrMirallas · @DrYukselUrun · @Lucarecco · @mzugman · @HHorinouchi · @p_ciracimd · @DraMartinezLago · @DrVilmaPBarcia · @GIMedOnc · @MarioBalsaMD · @scocmem · @AmandaNizamMD · @GaiaGriguolo · @JankovicK · @Dr_Oncologista · @Erman_Akkus · @WeOncologists · @niklas_kluemper · @Markuseckstein3

View quoted post on X